Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Taravini, Irene Re ^a   Chertoff, Mariela ^b   Cafferata, Eduardo G ^b   Courty, José ^c   Murer, Mario G ^d   Pitossi, Fernando J ^b   Gershanik, Oscar S ^a  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c Laboratoire CRRET Croissance Cellulaire Reparation et Regeneration Tissulaire ^*  (France)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PLEIOTROPHIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

ADENOVIRIDAE; ANIMALIA; PARKINSONIA; RATTUS;

EID: 79957954997     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-40     Document Type: Article

References (38)

1. Description of Parkinson's disease as a clinical syndrome. Fahn S, Ann N Y Acad Sci 2003 991 1 14 12846969 (Pubitemid 36793796)
2. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Goetz CG, Poewe W, Rascol O, Sampaio C, Mov Disord 2005 20 523 539 10.1002/mds.20464 15818599 (Pubitemid 40862249)
3. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Isacson O, Bjorklund LM, Schumacher JM, Ann Neurol 2003 53 Suppl 3 135 146
4. Treatment of Parkinson's disease with trophic factors. Peterson AL, Nutt JG, Neurotherapeutics 2008 5 270 280 10.1016/j.nurt.2008.02.003 18394569 (Pubitemid 351454059)
5. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. Rauvala H, EMBO J 1989 8 2933 2941 2583087 (Pubitemid 19274995)
6. HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Rauvala H, Peng HB, Prog Neurobiol 1997 52 127 144 10.1016/S0301-0082(97)00007-5 9185236 (Pubitemid 27242703)
7. Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Hida H, Jung CG, Wu CZ, Kim HJ, Kodama Y, Masuda T, Nishino H, Eur J Neurosci 2003 17 2127 2134 10.1046/j.1460-9568.2003.02661.x 12786979 (Pubitemid 36713973)
8. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. Ferrario JE, Taravini IR, Mourlevat S, Stefano A, Delfino MA, Raisman-Vozari R, Murer MG, Ruberg M, Gershanik O, J Neurochem 2004 90 1348 1358 10.1111/j.1471-4159.2004. 02595.x 15341519 (Pubitemid 39223639)
9. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Marchionini DM, Lehrmann E, Chu Y, He B, Sortwell CE, Becker KG, Freed WJ, Kordower JH, Collier TJ, Brain Res 2007 1147 77 88 17368428 (Pubitemid 46584663)
10. Pleiotrophin mediates the neurotrophic effect of cyclic AMP on dopaminergic neurons: analysis of suppression-subtracted cDNA libraries and confirmation in vitro. Mourlevat S, Debeir T, Ferrario JE, Delbe J, Caruelle D, Lejeune O, Depienne C, Courty J, Raisman-Vozari R, Ruberg M, Exp Neurol 2005 194 243 254 10.1016/j.expneurol.2005.02.015 15899261 (Pubitemid 40719759)
11. Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells. Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H, FASEB J 2004 18 1237 1239 15180956 (Pubitemid 39561562)
12. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats. Ferrario JE, Rojas-Mayorquín AE, Saldãa-Ortega M, Salum C, Gomes MZ, Hunot S, Raisman-Vozari R, J Neurochem 2008 107 443 452 10.1111/j.1471-4159.2008.05640.x 18752647
13. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H, J Biol Chem 1994 269 12999 13004 8175719
14. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F, Neurobiol Dis 2010 37 630 640 10.1016/j.nbd.2009.11. 018 19969084
15. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi FJ, Neurobiol Dis 2006 24 183 193 10.1016/j.nbd.2006.06.013 16901708 (Pubitemid 44437611)
16. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Ferrari CC, Depino AM, Prada F, Muraro N, Campbell S, Podhajcer O, Perry VH, Anthony DC, Pitossi FJ, Am J Pathol 2004 165 1827 1837 10.1016/S0002-9440(10)63438-4 15509551 (Pubitemid 39435180)
17. Microglial cell population dynamics in the injured adult central nervous system. Ladeby R, Wirenfeldt M, Garcia-Ovejero D, Fenger C, Dissing-Olesen L, Dalmau I, Finsen B, Brain Res Brain Res Rev 2005 48 196 206 15850658 (Pubitemid 40585750)
18. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. Perry VH, Hume DA, Gordon S, Neuroscience 1985 15 313 326 10.1016/0306-4522(85)90215-5 3895031 (Pubitemid 16197076)
19. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Sauer H, Oertel WH, Neuroscience 1994 59 401 415 10.1016/0306-4522(94)90605-X 7516500 (Pubitemid 24098798)
20. Pleiotrophin promotes functional recovery after neural transplantation in rats. Hida H, Masuda T, Sato T, Kim TS, Misumi S, Nishino H, Neuroreport 2007 18 179 183 10.1097/WNR.0b013e328011398e 17301686
21. Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Vanderwinden JM, Mailleux P, Schiffmann SN, Vanderhaeghen JJ, Anat Embryol (Berl) 1992 186 387 406
22. Developmentally regulated expression of pleiotrophin, a novel heparin binding growth factor, in the nervous system of the rat. Wanaka A, Carroll SL, Milbrandt J, Brain Res Dev Brain Res 1993 72 133 144 8453763 (Pubitemid 23070363)
23. A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells. Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, Worden L, Freed WJ, PLoS One 2009 4 6606 10.1371/journal.pone.0006606 19672298
24. Pleiotrophin prevents cocaine-induced toxicity in vitro. Gramage E, Alguacil LF, Herradon G, Eur J Pharmacol 2008 595 35 38 10.1016/j.ejphar.2008. 07.067 18727926
25. High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule. Milev P, Chiba A, Häring M, Rauvala H, Schachner M, Ranscht B, Margolis RK, Margolis RU, J Biol Chem 1998 273 6998 7005 10.1074/jbc.273.12.6998 9507007 (Pubitemid 28160367)
26. Are growth factors the answer? Ramaswamy S, Kordower JH, Parkinsonism Relat Disord 2009 15 Suppl 3 176 180
27. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H, Saarma M, Männistö PT, Exp Neurol 2009 219 499 506 10.1016/j.expneurol.2009.07. 002 19615368
28. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Björklund A, Rosenblad C, Winkler C, Kirik D, Neurobiol Dis 1997 4 186 200 10.1006/nbdi.1997.0151 9361295 (Pubitemid 27465509)
29. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L, Nature 1995 373 335 339 10.1038/373335a0 7830766
30. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Déglon N, Aebischer P, Science 2000 290 767 773 10.1126/science.290.5492.767 11052933
31. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D, J Neurosci 2005 25 769 777 10.1523/JNEUROSCI.4421-04.2005 15673656 (Pubitemid 40170991)
32. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD, Ann Neurol 1999 46 419 424 10.1002/1531-8249(199909)46: 3<419::AID-ANA21>3.0.CO;2-Q 10482276 (Pubitemid 29416283)
33. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor: Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF, ICV GDNF Study Group, Neurology 2003 60 69 73 12525720 (Pubitemid 36070646)
34. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS, Ann Neurol 2005 57 298 302 10.1002/ana.20374 15668979 (Pubitemid 40179870)
35. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, Milbrandt J, Deuel TF, Science 1990 250 1690 1694 10.1126/science.2270483 2270483 (Pubitemid 120031872)
36. The Rat Brain in Stereotaxic Coordinates. Paxinos G, Watson C, Academic Press, San Diego 1986
37. Immunodetection of heparin-binding growth associated molecule (pleiotrophin) in striatal interneurons. Taravini IR, Ferrario JE, Delbe J, Ginestet L, Debeir T, Courty J, Murer MG, Gershanik OS, Raisman-Vozari R, Brain Res 2005 1066 196 200 10.1016/j.brainres.2005.10.055 16325783 (Pubitemid 41790743)
38. Guidelines for the design and statistical analysis of experiments in papers submitted to ATLA (Alternatives to laboratory animals). Festing MF, Altern Lab Anim 2001 29 427 446 11506638 (Pubitemid 32830276)